CN112553324A - Primer, kit and method for detecting TREX1 gene mutation - Google Patents
Primer, kit and method for detecting TREX1 gene mutation Download PDFInfo
- Publication number
- CN112553324A CN112553324A CN202011575029.4A CN202011575029A CN112553324A CN 112553324 A CN112553324 A CN 112553324A CN 202011575029 A CN202011575029 A CN 202011575029A CN 112553324 A CN112553324 A CN 112553324A
- Authority
- CN
- China
- Prior art keywords
- trex1
- primer
- gene
- sequencing
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101150061787 Trex1 gene Proteins 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 18
- 206010064571 Gene mutation Diseases 0.000 title claims abstract description 14
- 238000012163 sequencing technique Methods 0.000 claims abstract description 36
- 230000035772 mutation Effects 0.000 claims abstract description 25
- 239000003153 chemical reaction reagent Substances 0.000 claims description 13
- 230000003321 amplification Effects 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 238000012408 PCR amplification Methods 0.000 claims description 8
- 238000007400 DNA extraction Methods 0.000 claims description 6
- 238000001514 detection method Methods 0.000 abstract description 10
- 208000033237 Aicardi-Goutières syndrome Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000007480 sanger sequencing Methods 0.000 abstract description 2
- 238000004393 prognosis Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 14
- 239000000523 sample Substances 0.000 description 12
- 238000001179 sorption measurement Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 101000830956 Homo sapiens Three-prime repair exonuclease 1 Proteins 0.000 description 10
- 102100024855 Three-prime repair exonuclease 1 Human genes 0.000 description 9
- 239000007788 liquid Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108700024394 Exon Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101000620808 Homo sapiens Dexamethasone-induced Ras-related protein 1 Proteins 0.000 description 2
- 101001103771 Homo sapiens Ribonuclease H2 subunit A Proteins 0.000 description 2
- 101000670585 Homo sapiens Ribonuclease H2 subunit C Proteins 0.000 description 2
- 102100039493 Ribonuclease H2 subunit A Human genes 0.000 description 2
- 102100039474 Ribonuclease H2 subunit B Human genes 0.000 description 2
- 102100039610 Ribonuclease H2 subunit C Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 208000021024 autosomal recessive inheritance Diseases 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000012295 chemical reaction liquid Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000010445 Chilblains Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 1
- 101710150629 Dynein light chain Tctex-type 1 Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 101000641031 Homo sapiens Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Proteins 0.000 description 1
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 1
- 101000904748 Homo sapiens G-protein-signaling modulator 1 Proteins 0.000 description 1
- 101000904749 Homo sapiens G-protein-signaling modulator 3 Proteins 0.000 description 1
- 101001103768 Homo sapiens Ribonuclease H2 subunit B Proteins 0.000 description 1
- 102000006445 IFIH1 Interferon-Induced Helicase Human genes 0.000 description 1
- 108010044240 IFIH1 Interferon-Induced Helicase Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 101710104624 Proline/betaine transporter Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000037340 Rare genetic disease Diseases 0.000 description 1
- 108700019718 SAM Domain and HD Domain-Containing Protein 1 Proteins 0.000 description 1
- 101150114242 SAMHD1 gene Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 208000021018 autosomal dominant inheritance Diseases 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000008133 cognitive development Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003793 prenatal diagnosis Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012487 rinsing solution Substances 0.000 description 1
- 102220003596 rs587776724 Human genes 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 108010068698 spleen exonuclease Proteins 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to a primer and a method for detecting TREX1 gene mutation, which comprises a primer for amplifying a TREX1 gene full exon sequence; sanger sequencing technology and sequencing primers were used. The invention can rapidly detect the mutation of the whole exon of the TREX1 gene. The detection result completed by the method is accurate, and the Aicardi-Goutieres syndrome can be diagnosed in an auxiliary way, so that the method has important reference significance for the diagnosis and prognosis of diseases.
Description
Technical Field
The invention belongs to the field of molecular detection, and particularly relates to a kit and a detection method for detecting TREX1 gene mutation.
Background
Aicardi-Goutieres syndrome (AGS) is a group of rare genetic diseases mainly involving nervous system and skin, most of the children with normal indexes at birth may have attacks within days or 1 month after birth, and the diseases are manifested as severe subacute encephalopathy such as epileptic seizures, chilblain-like skin rashes on the skin and aseptic fever, and are usually manifested as feeding difficulty, irritability, retrograde psychomotor or development retardation. Some patients in neonatal period are characterized by hepatosplenomegaly and thrombocytopenia. Symptoms stabilize after several months of progression. Although the symptoms of most children are rapidly developed within 1 year after birth, some children are also in a slow development process, and the main symptoms include dystonia, dyskinesia or cognitive development retardation.
The disease is mostly autosomal recessive inheritance, and a few autosomal dominant inheritance. Literature research shows that 7 pathogenic genes, including TREX1(AGS1), RNASEH2B (AGS2), RNASEH2C (AGS3), RNASEH2A (AGS4), SAMHD1(AGS5), ADAR1(AGS7) and IFIH1(AGS7) genes, have been found to date, and the occurrence of gene mutations in these genes can cause corresponding diseases of AGS1-7 type respectively. Wherein the TREX1 mutation causes AGS1 to occur.
The TREX1 gene is located on chromosome 3p21.31, and has 2 exons, and the first exon does not code for amino acid. The gene codes a nucleoprotein with 3' exonuclease activity, which comprises 4 highly conserved acidic residues positioned at the active site of an exonuclease DnaQ family, and the residues coordinate two Mg2+Has important function in catalysis. The adjacent active site and dimer structure in each TREX1 protein is PPII, which may play an important role in the interaction with the SET complex. TREXl proteins have an extended C-hydroxyl terminal transmembrane domain that is involved in subcellular localization of TREXl proteins in the cytoplasmic endoplasmic reticulum. Finally, a soft circular structure is arranged near each active site to be combined with DNA. Mutations in the TREX1 gene can lead to AGS syndrome, lupus erythematosus, Cree encephalitis, and other immune system diseases. Alternative splicing also results in multiple transcript variations. When TREXl gene is mutated, nuclear protein expression is reduced, dysfunction and even function loss are caused, so that accumulation of DNA double-strand degradation intermediates is caused to activate an autoimmune system, and then diseases of the autoimmune system are caused. The gene mutation forms reported at present are various and comprise base substitution, deletion and insertion. The TREX1 gene associated with AGS has been found to mutate by up to 32. The study of Li Hui Juan shows that the insertion mutation of the first exon c.460insA leads to the frame shift mutation of the 154-th 156-th amino acid and the advanced appearance of the 156-th stop codon TAG, thereby leading to the truncation of the TREXl protein, cutting off part of two Mg + coordination binding regions with catalytic action and a transmembrane region domain of the C-hydroxyl end, and influencing the protein function. The Lee-Kirsch et al study showed that most of the TREX1 genes in children with lupus manifestations were detected as heterozygous mutations and located at the functional end of the C' hydroxyl group, but the results of this study were to be confirmed in further experiments. The studies of Guohongwei et al indicated that c.45G > T, c.139G > A and c.459_460insA were not pathogenic when carried alone, and that three mutations were elicited when carried by one person at the same timeCausing disease.
The TREX1 mutation analysis has important significance for AGS genetic consultancy and prenatal diagnosis, the AGS genetic mode is autosomal recessive inheritance, and the TREX mutation analysis has important significance for families with parents being heterozygous mutations. And the patient is younger in age, prevention of the disease needs to be controlled in the prenatal stage, either parent (mutation carrier) has no disease symptoms, and each offspring has one quarter of the possible two defective genes, thus inheriting AGS. Therefore, if the pathogenic gene of the proband is clear, parents decide that the pregnancy needs to carry out related genetic counseling in time, and prenatal molecular diagnosis is carried out at the early stage of the pregnancy, so that the birth of abnormal fetuses is reduced to the maximum extent, and the population quality of newborn infants is improved.
Disclosure of Invention
The invention aims to provide a kit for detecting TREX1 gene mutation, which can be used for rapidly detecting the TREX1 gene mutation condition in a patient by adopting a PCR (polymerase chain reaction) technology.
The primer for detecting the TREX1 gene mutation is characterized by comprising a primer for amplifying a TREX1 gene, wherein the base sequence of the primer is as follows:
TREX1-1F:TGTAAAACGACGGCCAGT GGGAACGGATGGTGGTGA
TREX1-1R:AACAGCTATGACCATG AGGGTGAGGTGGTTTCCTTAG
TREX1-2F1:TGTAAAACGACGGCCAGT TCGCAGACAGGGCAGGATTG
TREX1-2R1:AACAGCTATGACCATG CACTGGTGAGGCCCAGCATAG
TREX1-2F2:TGTAAAACGACGGCCAGT CCAACCTGCTCCTAGCCTTCC
TREX1-2R2:AACAGCTATGACCATG GACAAACACTGTGCCCTCCTC。
further, the primers also comprise a sequencing primer for detecting the TREX1 gene, and the base sequence of the sequencing primer is as follows:
M13F:TGTAAAACGACGGCCAGT
M13R:AACAGCTATGACCATG。
the invention also provides a method for detecting the mutation condition of the TREX1 gene, which comprises the following steps:
(1) extracting tissue DNA in blood;
(2) carrying out PCR amplification on the DNA extracted in the step (1) to obtain an amplification primer; wherein the base sequence of the PCR amplification primer is as follows:
TREX1-1F:TGTAAAACGACGGCCAGT GGGAACGGATGGTGGTGA
TREX1-1R:AACAGCTATGACCATG AGGGTGAGGTGGTTTCCTTAG
TREX1-2F1:TGTAAAACGACGGCCAGT TCGCAGACAGGGCAGGATTG
TREX1-2R1:AACAGCTATGACCATG CACTGGTGAGGCCCAGCATAG
TREX1-2F2:TGTAAAACGACGGCCAGT CCAACCTGCTCCTAGCCTTCC
TREX1-2R2:AACAGCTATGACCATG GACAAACACTGTGCCCTCCTC。
(3) sequencing the amplification product in the step (2) by using a pair of sequencing primers, wherein the base sequences of the pair of sequencing primers are as follows:
M13F:TGTAAAACGACGGCCAGT
M13R:AACAGCTATGACCATG;
(4) judging the sequencing result to determine whether the TREX1 gene is mutated.
The invention also provides a kit for detecting the TREX1 gene mutation site, which comprises:
(i) blood DNA extraction reagent;
(ii) detecting a system PCR amplification reaction solution; comprises a primer for amplifying a TREX1 gene, and the base sequence of the primer is as follows:
TREX1-1F:TGTAAAACGACGGCCAGT GGGAACGGATGGTGGTGA
TREX1-1R:AACAGCTATGACCATG AGGGTGAGGTGGTTTCCTTAG
TREX1-2F1:TGTAAAACGACGGCCAGT TCGCAGACAGGGCAGGATTG
TREX1-2R1:AACAGCTATGACCATG CACTGGTGAGGCCCAGCATAG
TREX1-2F2:TGTAAAACGACGGCCAGT CCAACCTGCTCCTAGCCTTCC
TREX1-2R2:AACAGCTATGACCATG GACAAACACTGTGCCCTCCTC。
(iii) sequencing system reagents; comprises a sequencing primer for detecting a TREX1 gene, and the base sequence of the sequencing primer is as follows:
M13F:TGTAAAACGACGGCCAGT
M13R:AACAGCTATGACCATG。
has the advantages that: the invention designs a primer for amplifying all 2 exon sequences of TREX 1. By adding the adaptor, the PCR products of 3 pairs of primers can be sequenced by using one sequencing primer. A stable amplification system is constructed by adopting a PCR technology. By adjusting the reaction conditions such as primer concentration and annealing temperature, the amplification efficiency can be optimized. The mutation types of the TREX1 gene are various and are distributed throughout the whole gene, so that the primers disclosed by the invention can amplify the TREX1 whole exon sequences, and ensure that the condition of omission does not occur no matter where the exons are mutated. Compared with a fluorescent quantitative PCR method, the invention reduces the cost and difficulty of detection. The fluorescent quantitative PCR method needs to design a plurality of probes aiming at different mutation types, and has high cost and great detection difficulty.
Drawings
FIG. 1 is a map of the chromosomal location of the TREX1 gene.
FIGS. 2, 3 and 4 are electrophoresis diagrams of amplified products after amplification by primers TREX1-1F \1R, TREX1-2F1\2R1 and TREX1-2F2\2R2 respectively, wherein M is Marker DL 2000, the primers TREX1-1F \1R, TREX1-2F1\2R1 and TREX1-2F2\2R2 are effective in amplification and bright in band.
FIG. 5 shows a sequence screenshot of the mutant of exon No. TREX 11, indicating that exon No. 1 c. -68 of the sample is partially mutated T > TC.
FIG. 6 shows a TREX 11 exon mutant sequencing screenshot illustrating the partial mutation C > CT of exon 1C-60 in the sample.
FIG. 7 shows a TREX 12 exon mutant sequencing screenshot illustrating the partial mutation C > CT of exon 2 c.266 in the sample.
FIG. 8 shows a sequence screenshot of the mutant of exon No. 2 of TREX 12, indicating that the partial mutation of exon No. 2 c.531 is T > TC.
FIG. 9 shows a TREX 12 exon mutant sequencing screenshot demonstrating the complete mutation T > C in exon 2 c.531 of the sample.
Detailed Description
The invention will be further elucidated with reference to the specific embodiments and the accompanying drawings. It should be noted that the conventional conditions and methods not described in the examples are generally employed by those skilled in the art according to the routine procedures: such as OsOb and Kingston, fourth edition, or following the manufacturer's suggested procedures and conditions.
Example 1
The primer for detecting the mutation site of the TREX1 gene is designed to be an amplification primer designed aiming at the whole exon of TREX1, and comprises the following components:
the primer for amplifying the whole exon sequence of the TREX1 gene has the base sequence as follows:
TREX1-1F:TGTAAAACGACGGCCAGT GGGAACGGATGGTGGTGA
TREX1-1R:AACAGCTATGACCATG AGGGTGAGGTGGTTTCCTTAG
TREX1-2F1:TGTAAAACGACGGCCAGT TCGCAGACAGGGCAGGATTG
TREX1-2R1:AACAGCTATGACCATG CACTGGTGAGGCCCAGCATAG
TREX1-2F2:TGTAAAACGACGGCCAGT CCAACCTGCTCCTAGCCTTCC
TREX1-2R2:AACAGCTATGACCATG GACAAACACTGTGCCCTCCTC。
a kit for detecting TREX1 gene mutation, comprising:
(i) blood DNA extraction reagent;
(ii) detecting a system PCR reaction solution;
(iii) sequencing system reagents;
the tissue DNA extraction reagent can be purchased from commercial reagents such as Tiangen DNA extraction kit and the like.
The PCR amplification reaction solution of the detection system comprises: 2 times PCR Buffer; 2mM dNTPs; KOD FX DNApolymerase (1U/. mu.l); the concentrations of upstream primer TREX1-1F/1R, TREX1-2F1/2R1 and TREX1-2F2/2R2 primer of 2 exon sequences of TREX1 gene are 10 mu M.
The sequencing system reagent comprises: sequencing purification solution (ExoI:0.6U, CIP:1.2U), EDTA (125mmol), absolute ethanol, 75% ethanol, HIDI (highly deionized formamide), sequencing primers: the upstream and downstream primers for detecting the whole exon sequence of TREX1 gene were M13F (3.2 μ M), M13R (3.2 μ M), and Bigdye Terminator V3.1 (purchased from Applied Biosystems, USA), respectively. Among them, FIG. 1 is a map of the chromosomal location of the TREX1 gene.
Example 2
The operation flow of the blood/cell/tissue genome DNA extraction kit (Tiangen organism):
(1) extracting tissue DNA from blood:
1) mu.l of blood was taken and added to 900. mu.l of erythrocyte lysate, mixed by inversion, left at room temperature for 5 minutes, and mixed by inversion several times in the meantime. Centrifuging at 12000rpm for 1min, removing supernatant, collecting leukocyte precipitate, adding 200 μ l buffer solution GA, and shaking to thoroughly mix;
2) adding 20 mul proteinase K solution, and mixing;
3) adding 200 μ l buffer solution GB, fully reversing and mixing, standing at 70 deg.C for 10 min, cleaning the solution, and centrifuging briefly to remove water droplets on the inner wall of the tube cover;
4) adding 200 μ l of anhydrous ethanol, shaking thoroughly, mixing for 15s, wherein flocculent precipitate may appear, and centrifuging briefly to remove water drops on the inner wall of the tube cover;
5) adding the solution and flocculent precipitate obtained in the previous step into an adsorption column CB3 (the adsorption column is placed into a collecting pipe), centrifuging at 12000rpm for 30 s, pouring off waste liquid, and placing the adsorption column CB3 back into the collecting pipe;
6) adding 500 μ l buffer GD (before use, whether absolute ethyl alcohol is added or not is checked), centrifuging at 12000rpm for 30 s, pouring off waste liquid, and putting adsorption column CB3 into a collection tube;
7) adding 700 μ l of rinsing solution PW (checking whether anhydrous ethanol is added before use) into adsorption column CB3, centrifuging at 12000rpm for 30 s, pouring off waste liquid, and placing adsorption column CB3 into a collection tube;
8) adding 500 μ l of rinsing liquid PW into adsorption column CB3, centrifuging at 12,000 rpm for 30 s, and pouring off waste liquid;
9) the adsorption column CB3 was returned to the collection tube, centrifuged at 12,000 rpm for 2 minutes, and the waste liquid was discarded. Placing the adsorption column CB3 at room temperature for a plurality of minutes to thoroughly dry the residual rinsing liquid in the adsorption material;
10) transferring the adsorption column CB3 into a clean centrifuge tube, suspending and dripping 100 mu l of elution buffer TE into the middle part of the adsorption membrane, standing for 2-5 minutes at room temperature, centrifuging for 2 minutes at 12,000 rpm, and collecting the solution into the centrifuge tube.
(2) Reagent preparation: preparing X mul of PCR reaction liquid of a detection system according to the parts of detected people, and subpackaging 19 mul of PCR reaction liquid of each part of detected people:
19. mu.l reaction solution X (n parts specimen +1 part blank control)
And n is the number of detected samples.
(3) Sample adding: adding 1 mul DNA into the PCR reaction solution of the detection system; blank control was supplemented with 1. mu.l of physiological saline or nothing.
(4) Amplification: the detection is carried out on a conventional PCR instrument, and available instruments include ABI veriti (Applied Biosystems, USA) and the like. The reaction conditions were as follows:
the preparation method of the PCR amplification system reagent comprises the following steps:
the primer F/R is selected from TREX1-1F/1R, TREX1-2F1/2R1 and TREX1-2F2/2R 2.
Wherein, the related information of the primers is shown as follows, and the sequences of the primers are shown as example 1:
(5) electrophoresis: electrophoresis on 1.5% agarose gel at 110V for 25min, and observation on a gel imaging system.
(6) Sanger sequencing:
take 9. mu.l of PCR product and 2. mu.l of purification system. Purification was performed according to the following procedure:
mu.l of the purified product was mixed with the upper and lower sequencing primers, respectively, according to the following system:
reaction procedure:
and (3) a precipitation link:
adding 2 mu l of 125mmol EDTA into the product after the sequencing reaction, and standing for 5 min; adding 15 mul of absolute ethyl alcohol, and mixing evenly by vortex; centrifuging at 3700rpm for 30 min; inverting, centrifuging for 15sec, adding 50 μ l 70% ethanol, and mixing by vortex; centrifuging at 3700rpm for 15 min; inverting and centrifuging for 15sec, and placing on a metal bath at 95 ℃; denaturation test was performed after adding 10. mu.l Hi-Di.
After the denaturation procedure was completed, sequencing was performed using a sequencer (ABI 3730).
(7) And (5) judging a result: the sequencing results were compared to the TREX1 wild-type reference sequence (Genbank: NG-041782), respectively, and the results were reported as a function of the actual mutation.
Example 3
24 clinical samples were taken and genomic extraction, reagent formulation, amplification and sequencing were performed according to the reagents and methods of examples 1 and 2. Mu.l of sample was added to each PCR reaction solution. FIGS. 2, 3 and 4 are the electropherograms of the amplified products obtained after the blood sample is amplified by using TREX1-1F/1R, TREX1-2F1/2R1 and TREX1-2F2/2R2 as primers. The lengths of the amplified fragments are 337bp, 587bp and 768bp respectively, and analysis of an electrophoretogram shows that the primers TREX1-1F/1R, TREX1-2F1/2R1 and TREX1-2F2/2R2 are effective in amplification and single in band.
The sequencing results of 24 samples showed the presence of 5 mutation sites, each of which and the number of which are shown in the following table:
FIG. 5 shows a sequence screenshot of the mutant of exon No. TREX 11, indicating that exon No. 1 c. -68 of the sample is partially mutated T > TC.
FIG. 6 shows a TREX 11 exon mutant sequencing screenshot illustrating the partial mutation C > CT of exon 1C-60 in the sample.
FIG. 7 shows a TREX 12 exon mutant sequencing screenshot illustrating the partial mutation C > CT of exon 2 c.266 in the sample.
FIG. 8 shows a sequence screenshot of the mutant of exon No. 2 of TREX 12, indicating that the partial mutation of exon No. 2 c.531 is T > TC.
FIG. 9 shows a TREX 12 exon mutant sequencing screenshot demonstrating the complete mutation T > C in exon 2 c.531 of the sample.
As can be seen from the detection results, the primers of the invention already include exon sequences, can expand 2 exons of TREX1 gene, and the sequencing result is completely accurate. The primer provided by the invention can accurately expand the TREX1 gene full exon, whether the TREX1 gene is a wild type or a mutant type.
Sequence listing
<110> Jinan Aidean medical testing center Limited
<120> primers, kit and method for detecting TREX1 gene mutation
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 36
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
tgtaaaacga cggccagtgg gaacggatgg tggtga 36
<210> 2
<211> 37
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
aacagctatg accatgaggg tgaggtggtt tccttag 37
<210> 3
<211> 38
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
tgtaaaacga cggccagttc gcagacaggg caggattg 38
<210> 4
<211> 37
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
aacagctatg accatgcact ggtgaggccc agcatag 37
<210> 5
<211> 39
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
tgtaaaacga cggccagtcc aacctgctcc tagccttcc 39
<210> 6
<211> 37
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
aacagctatg accatggaca aacactgtgc cctcctc 37
<210> 7
<211> 18
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
<210> 8
<211> 16
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
Claims (4)
1. The primer for detecting the TREX1 gene mutation is characterized by comprising a primer for amplifying a TREX1 gene, wherein the base sequence of the primer is as follows:
TREX1-1F:TGTAAAACGACGGCCAGT GGGAACGGATGGTGGTGA
TREX1-1R:AACAGCTATGACCATG AGGGTGAGGTGGTTTCCTTAG
TREX1-2F1:TGTAAAACGACGGCCAGT TCGCAGACAGGGCAGGATTG
TREX1-2R1:AACAGCTATGACCATG CACTGGTGAGGCCCAGCATAG
TREX1-2F2:TGTAAAACGACGGCCAGT CCAACCTGCTCCTAGCCTTCC
TREX1-2R2:AACAGCTATGACCATG GACAAACACTGTGCCCTCCTC。
2. the primer of claim 1, further comprising a sequencing primer for detecting TREX1 gene, wherein the base sequence is:
M13F:TGTAAAACGACGGCCAGT
M13R:AACAGCTATGACCATG。
3. a method for detecting the mutation condition of TREX1 gene, which comprises the following steps:
(1) extracting tissue DNA in blood;
(2) carrying out PCR amplification on the DNA extracted in the step (1) to obtain an amplification primer; wherein the base sequence of the PCR amplification primer is as follows:
TREX1-1F:TGTAAAACGACGGCCAGT GGGAACGGATGGTGGTGA
TREX1-1R:AACAGCTATGACCATG AGGGTGAGGTGGTTTCCTTAG
TREX1-2F1:TGTAAAACGACGGCCAGT TCGCAGACAGGGCAGGATTG
TREX1-2R1:AACAGCTATGACCATG CACTGGTGAGGCCCAGCATAG
TREX1-2F2:TGTAAAACGACGGCCAGT CCAACCTGCTCCTAGCCTTCC
TREX1-2R2:AACAGCTATGACCATG GACAAACACTGTGCCCTCCTC;
(3) sequencing the amplification product in the step (2) by using a pair of sequencing primers, wherein the base sequences of the pair of sequencing primers are as follows:
M13F:TGTAAAACGACGGCCAGT
M13R:AACAGCTATGACCATG;
(4) judging the sequencing result to determine whether the TREX1 gene is mutated.
4. A kit for detecting a TREX1 gene mutation site, which is characterized by comprising:
(i) blood DNA extraction reagent;
(ii) detecting a system PCR amplification reaction solution; comprises a primer for amplifying a TREX1 gene, and the base sequence of the primer is as follows:
TREX1-1F:TGTAAAACGACGGCCAGT GGGAACGGATGGTGGTGA
TREX1-1R:AACAGCTATGACCATG AGGGTGAGGTGGTTTCCTTAG
TREX1-2F1:TGTAAAACGACGGCCAGT TCGCAGACAGGGCAGGATTG
TREX1-2R1:AACAGCTATGACCATG CACTGGTGAGGCCCAGCATAG
TREX1-2F2:TGTAAAACGACGGCCAGT CCAACCTGCTCCTAGCCTTCC
TREX1-2R2:AACAGCTATGACCATG GACAAACACTGTGCCCTCCTC;
(iii) sequencing system reagents; comprises a sequencing primer for detecting a TREX1 gene, and the base sequence of the sequencing primer is as follows:
M13F:TGTAAAACGACGGCCAGT
M13R:AACAGCTATGACCATG。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011575029.4A CN112553324A (en) | 2020-12-28 | 2020-12-28 | Primer, kit and method for detecting TREX1 gene mutation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011575029.4A CN112553324A (en) | 2020-12-28 | 2020-12-28 | Primer, kit and method for detecting TREX1 gene mutation |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112553324A true CN112553324A (en) | 2021-03-26 |
Family
ID=75033657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011575029.4A Pending CN112553324A (en) | 2020-12-28 | 2020-12-28 | Primer, kit and method for detecting TREX1 gene mutation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112553324A (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100104579A1 (en) * | 2006-09-25 | 2010-04-29 | Technische Universitat Dresden | Trex1 as a marker for lupus erythematosus |
CN106967819A (en) * | 2017-05-03 | 2017-07-21 | 济南艾迪康医学检验中心有限公司 | Detect the kit and method of hyper-IgE syndrome STAT3 gene mutations |
CN107058531A (en) * | 2017-04-01 | 2017-08-18 | 杭州艾迪康医学检验中心有限公司 | A kind of kit and method for detecting Niemann-Pick disease SMPD1 gene mutations |
CN109371123A (en) * | 2018-12-24 | 2019-02-22 | 中国医学科学院北京协和医院 | For detecting the probe groups and kit of auto-inflammatory disease Disease-causing gene |
-
2020
- 2020-12-28 CN CN202011575029.4A patent/CN112553324A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100104579A1 (en) * | 2006-09-25 | 2010-04-29 | Technische Universitat Dresden | Trex1 as a marker for lupus erythematosus |
CN107058531A (en) * | 2017-04-01 | 2017-08-18 | 杭州艾迪康医学检验中心有限公司 | A kind of kit and method for detecting Niemann-Pick disease SMPD1 gene mutations |
CN106967819A (en) * | 2017-05-03 | 2017-07-21 | 济南艾迪康医学检验中心有限公司 | Detect the kit and method of hyper-IgE syndrome STAT3 gene mutations |
CN109371123A (en) * | 2018-12-24 | 2019-02-22 | 中国医学科学院北京协和医院 | For detecting the probe groups and kit of auto-inflammatory disease Disease-causing gene |
Non-Patent Citations (2)
Title |
---|
何庭艳等: "Aicardi-Goutières综合征", 《中国实用儿科杂志》 * |
郭起浩等: "《血管性认知损害》", 31 May 2019, 上海科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jezewski et al. | Complete sequencing shows a role for MSX1 in non-syndromic cleft lip and palate | |
Numasawa et al. | Nasu–Hakola disease with a splicing mutation of TREM2 in a Japanese family | |
Alkelai et al. | Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family‐based, Arab‐Israeli sample | |
CN109576367B (en) | Primers, kit and method for detecting BCOR gene mutation | |
Ferraris et al. | HDR syndrome: a novel “de novo” mutation in GATA3 gene | |
CN106987642A (en) | Detect the kit and method of the full extron of MPL genes | |
CN106834287B (en) | SNP marker for detecting RhD negative phenotype | |
CN105755132B (en) | Method, oligonucleotide and kit for detecting WAS gene polymorphic mutation site | |
CN110951862A (en) | Method, primer and kit for detecting CYP21A2 gene mutation | |
CN114703278A (en) | Amyotrophic lateral sclerosis pathogenic gene, detection kit and primer group | |
Chua et al. | Association of NOD1, CXCL16, STAT6 and TLR4 gene polymorphisms with Malaysian patients with Crohn’s disease | |
Che et al. | Identification of two novel variants of the BCL11B gene in two Chinese pedigrees associated with neurodevelopmental disorders | |
CN111004849B (en) | Primer, method and kit for detecting multiple site mutations of CDH1 gene | |
CN112553324A (en) | Primer, kit and method for detecting TREX1 gene mutation | |
CN109628563A (en) | Detect primer, kit and the method in the mutational site PIGA gene promoter region 4972A > G | |
US5882868A (en) | Method of diagnosing spinal muscular atrophy | |
CN114032303A (en) | Oligonucleotide and method for detecting new mutation of gene ABCB11 | |
CN111733232A (en) | Primer, method and kit for detecting HBB gene mutation | |
CN107058531A (en) | A kind of kit and method for detecting Niemann-Pick disease SMPD1 gene mutations | |
CN106868184B (en) | Method, kit and oligonucleotide for detecting PKLR gene mutation and application thereof | |
Li et al. | Gene mutation analysis and prenatal diagnosis of the ornithine transcarbamylase (OTC) gene in two families with ornithine transcarbamylase deficiency | |
Qian et al. | Novel mutations found in the ATP7B gene in Chinese patients with Wilson's disease | |
Yu et al. | Apparent homozygosity for a novel splicing variant in EPS8 causes congenital profound hearing loss | |
CN111057758A (en) | Primer and method for detecting PSEN1 gene mutation and application thereof | |
CN114381513B (en) | Biomarker related to X-linked lymphoproliferative disorder and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210326 |
|
RJ01 | Rejection of invention patent application after publication |